Xlife Sciences AG (SWX:XLS)

Market Cap	132.65M -12.2%
Revenue (ttm)	839.38K -15.2%
Net Income	30.75M +44.8%
EPS	4.54 +74.2%
Shares Out	5.77M
PE Ratio	5.06
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	5,171
Open	23.50
Previous Close	22.10
Day's Range	22.10 - 23.50
52-Week Range	15.75 - 28.00
Beta	0.38
RSI	39.24
Earnings Date	Apr 28, 2026

About Xlife Sciences AG

Xlife Sciences AG focuses on the development and commercialization of research projects in the life sciences sector. The company’s project covers technology platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health areas that focuses on identifying new therapeutic approaches and biomarkers for common diseases based on human genetic data. It also produces, researches, develops, and manufactures the chemical and active pharmaceutical ingredients for human and veterinary medicines; and offers clinical resea...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Employees: 17
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: XLS

Financial Performance

In 2024, Xlife Sciences AG's revenue was 834,877, a decrease of -15.54% compared to the previous year's 988,435. Earnings were 34.28 million, an increase of 130.37%.